Toca 6 Clinical Trial

Virus Treatment for Metastatic Cancer: Enrollment is Now Open for Patients with metastatic colorectal, breast, pancreatic, renal, lung, and melanoma

Participation in a clinical trial is one possible option for people who have cancer. It is recommended that patients talk with their doctor to discuss potential participation in a clinical trial.

The Toca 6 trial is a Phase 1b study evaluating intravenously delivered Toca 511 in combination with Toca FC in patients with metastatic cancers. The study is planned to include patients with colorectal cancer with liver metastases; metastatic renal cell carcinoma; locally advanced or metastatic pancreatic cancer or breast cancer; brain metastases from non-small cell lung cancer or breast cancers; and locally advanced or recurrent melanoma.

The trial will evaluate if Toca 511-delivered genes and resulting proteins are detected in tumor samples, following intravenous administration of Toca 511. Safety, tumor response and survival results will also be assessed.

Please fill out the Patient Inquiry Form to learn more about potential participation in the Toca 6 trial.

A patient may qualify for this study if the patient:

  • has metastatic cancer: colorectal, breast, lung, pancreatic, renal or melanoma
  • is a candidate for biopsy or resection of at least one lesion
  • is between 18 years old and 90 years old

Currently, this study is being offered in the United States. View a list of participating sites.

Learn more about the study including a full list of entry criteria.

Toca 511 & Toca FC are investigational products. An investigational product is one that has not been proven to be safe and effective for this use and is not licensed by the US Food and Drug Administration or any other government agency. An investigational product can only be administered in a research study.